Ministry of Health (Bahrain)

Bahrain, First in the Middle East to Acquire Latest Machine used for Human Genome Sequencing

Retrieved on: 
Tuesday, November 28, 2023
Ministry, Research, Ministry of Health (Bahrain), Al-Zahrawi, Emerging market, Genomics, Supreme Council, GCC, Harvard University, Medical device, Health, Illumina, Kingdom

MANAMA, Bahrain, Nov. 28, 2023 /PRNewswire/ -- The Ministry of Health in the Kingdom of Bahrain has become the first in the Middle East to acquire and inaugurate the use of the cutting-edge NovaSeqTM X Plus machine for human genome sequencing purposes.

Key Points: 
  • MANAMA, Bahrain, Nov. 28, 2023 /PRNewswire/ -- The Ministry of Health in the Kingdom of Bahrain has become the first in the Middle East to acquire and inaugurate the use of the cutting-edge NovaSeqTM X Plus machine for human genome sequencing purposes.
  • The move is part of the Kingdom's commitment to continue developing therapeutic and diagnostic services in line with latest global medical advancements, benefiting the health of all.
  • The Chairman of the Supreme Council of Health, Lt. General Dr. Shaikh Mohammed bin Abdulla Al Khalifa, highlighted the ongoing efforts within the National Genome Project, which aims to utilize gene sequencing in adopting effective national health policies and therapeutic and preventative management plans.
  • A national delegation of specialists from the National Genome Centre was sent to Harvard University in the United States to undergo specialized training, including the latest methods of genome sequencing, biological data classification, clinical analysis, scientific data analysis, and genetic data management.

Bahrain, First in the Middle East to Acquire Latest Machine used for Human Genome Sequencing

Retrieved on: 
Tuesday, November 28, 2023
Ministry, Research, Ministry of Health (Bahrain), Al-Zahrawi, Emerging market, Genomics, Supreme Council, GCC, Harvard University, Medical device, Health, Illumina, Kingdom

MANAMA, Bahrain, Nov. 28, 2023 /PRNewswire/ -- The Ministry of Health in the Kingdom of Bahrain has become the first in the Middle East to acquire and inaugurate the use of the cutting-edge NovaSeqTM X Plus machine for human genome sequencing purposes.

Key Points: 
  • MANAMA, Bahrain, Nov. 28, 2023 /PRNewswire/ -- The Ministry of Health in the Kingdom of Bahrain has become the first in the Middle East to acquire and inaugurate the use of the cutting-edge NovaSeqTM X Plus machine for human genome sequencing purposes.
  • The move is part of the Kingdom's commitment to continue developing therapeutic and diagnostic services in line with latest global medical advancements, benefiting the health of all.
  • The Chairman of the Supreme Council of Health, Lt. General Dr. Shaikh Mohammed bin Abdulla Al Khalifa, highlighted the ongoing efforts within the National Genome Project, which aims to utilize gene sequencing in adopting effective national health policies and therapeutic and preventative management plans.
  • A national delegation of specialists from the National Genome Centre was sent to Harvard University in the United States to undergo specialized training, including the latest methods of genome sequencing, biological data classification, clinical analysis, scientific data analysis, and genetic data management.

InaVac gets emergency approval from BPOM

Retrieved on: 
Monday, November 14, 2022
COVID-19, Pleasure, Food, University, Airlangga University, Ministry of Health (Bahrain), Ministry, EUA, Government, News, Research, Ageing, Vaccine, Pharmaceutical industry, Animal, Previously Unaired Christmas, Health

Surabaya, East Java, Indonesia, Nov 14, 2022 - (ACN Newswire) - The Food and Drug Supervisory Agency (BPOM) has issued emergency use authorization (EUA) for InaVac, a COVID-19 vaccine developed by researchers from Airlangga University (Unair).

Key Points: 
  • Surabaya, East Java, Indonesia, Nov 14, 2022 - (ACN Newswire) - The Food and Drug Supervisory Agency (BPOM) has issued emergency use authorization (EUA) for InaVac, a COVID-19 vaccine developed by researchers from Airlangga University (Unair).
  • InaVac, COVID-19 vaccine, is developed by the University of Airlangga in Surabaya, East Java Province.
  • (ANTARA/HO-BPBRIN Unair)
    "InaVac has obtained emergency use authorization from BPOM and will be mass-produced," the rector of Unair, Prof. Moh.
  • InaVac has been approved for use as a primary vaccine for people aged 18 and above for boosting immunity levels.

BERMUDA ANNOUNCES EARLY END TO TRAVEL AUTHORISATION REQUIREMENTS FOR TRAVELLERS

Retrieved on: 
Saturday, November 5, 2022
Public health, Ministry of Health (Bahrain), Ministry, TA, Industry, COVID, Safety, Legislation, Vaccination, JFK, BTA, COVID-19, Travel, Government, News, Tourism, Health

HAMILTON, Bermuda, Nov. 4, 2022 /PRNewswire/ -- Today, the Bermuda government announced the elimination of the travel authorisation (TA) process some (3) three weeks earlier than originally scheduled a move which will streamline the overall travel experience for visitors.

Key Points: 
  • Effective November 14, Bermuda will end the travel authorisation process offering a simpler travel experience for Bermuda's visitors.
  • HAMILTON, Bermuda, Nov. 4, 2022 /PRNewswire/ -- Today, the Bermuda governmentannounced the elimination of the travel authorisation (TA) process some (3) three weeks earlier than originally scheduled a move which will streamline the overall travel experience for visitors.
  • All non-residents who travel to Bermuda as of November 14 must complete the Bermuda Arrival Card even if they have previously completed a travel authorisation form.
  • The Bermuda Tourism Authority (BTA) promotes Bermuda globally as a world-class destination for leisure and group travel and tourism investment.

BioNTech CEO Ugur Sahin Visited Israel to Discuss Cooperation on Pandemic Preparedness and the Development of Innovative Medicines

Retrieved on: 
Wednesday, September 7, 2022
Hebrew University of Jerusalem, COVID-19, Regeneron Pharmaceuticals, Public health, CEO, Ministry, Cancer, Research, Epidemic, Ministry of Economy (Spain), Ministry of Health (Bahrain), Israel Innovation Authority, Private Securities Litigation Reform Act, Vaccine, BioNTech, Infection, Hoffmann-La Roche, SEC, Accountant, Nasdaq, Company, Therapy, Immunotherapy, Form, Ministry of Finance (Israel), Weizmann Institute of Science, Hadassah Medical Center, RNA transfection, BNTX, Viktor Genev, Pharmaceutical industry, Pfizer, Industry, Genentech, Health

The visit was set to promote the potential cooperation between the State of Israel, its academic institutions and BioNTech on pandemic preparedness and discuss potential research collaborations aimed at developing innovative medicines.

Key Points: 
  • The visit was set to promote the potential cooperation between the State of Israel, its academic institutions and BioNTech on pandemic preparedness and discuss potential research collaborations aimed at developing innovative medicines.
  • In addition, the discussions also included the possibility of the establishment of a research and production facility in Israel.
  • Prof. Sahin also held a lecture at the Weizmann Institute on the potential of mRNA vaccines and therapeutics.
  • Orna Barbivay, Minister of Economy and Industry of Israel, said: Israel works to find technological solutions to epidemics and diseases.

Emergex Vaccines signs Heads of Terms for a Collaboration with Molecular Biology Institute of Paraná (IBMP) in Brazil

Retrieved on: 
Friday, July 1, 2022
Department, IBMP, Official development assistance, Research, UKM Medical Molecular Biology Institute, Molecular biology, COVID-19, Ministry, Ministry of Health (Bahrain), DHSC, Secretary of State for International Development, Innovate UK, Social, Vaccine, Innovation, SBRI, Dengue fever, Pharmaceutical industry, Health

In addition, clinical stage manufacturing of the vaccines will be conducted by Emergex with a transition to commercial scale manufacturing being conducted in the region by IBMP.

Key Points: 
  • In addition, clinical stage manufacturing of the vaccines will be conducted by Emergex with a transition to commercial scale manufacturing being conducted in the region by IBMP.
  • A Joint Steering Committee with representatives from both Emergex and IBMP will oversee the collaboration and commercialisation of the vaccines in Brazil.
  • The collaboration also involves Emergex and IBMP conducting pre-clinical testing and clinical development of Chikungunya vaccine candidate.
  • Partnering with IBMP makes strategic sense for Emergex as it has the local contacts and expertise to successfully develop and commercialize our vaccines in Brazil.

RCSI Bahrain continues to meet Global Healthcare Educational Standards and support the development of national healthcare programmes in the Gulf Countries

Retrieved on: 
Tuesday, May 10, 2022
Medical Council, Bahrain Royal Medical Services, Ministry, Royal college, RCSI-Bahrain, University, Ministry of Education (Malaysia), Gulf, Hospital, Knowledge, Accreditation, Ministry of Health (Bahrain), Medical school, Master of Science, NQF, School, World Directory of Medical Schools, Central Waqf Council, Lists of schools in England, RCSI, World government, Cleveland Clinic, Medicine, Student, Salmaniya Medical Complex, WFME, Education, UNESCO, University of Limerick, BQA, GLOBE, Nepal Ayurvedic Medical Council, National qualifications framework, Review, International Association, Medical Council of Ireland, American Mission Hospital, Quality, Royal College of Surgeons in Ireland, Midwifery, IMC, Research, Nursing, Health, Council

The IMC issued a five-year renewal of the accreditation of the undergraduate medicine programme, which is valid until November 2026.

Key Points: 
  • The IMC issued a five-year renewal of the accreditation of the undergraduate medicine programme, which is valid until November 2026.
  • President of RCSI Bahrain, Professor Sameer Otoom commented, With our accreditation standards and a world-renowned curriculum, RCSI Bahrain graduates attain a level of knowledge and clinical experience to compete for rewarding career opportunities worldwide, as well as supporting the development of national healthcare programmes in the Gulf Countries.
  • RCSI Bahrain is a constituent university of RCSI, which was established in Dublin, Ireland, in 1784.
  • RCSI Bahrain, an independent private university, opened its doors to a cohort of 28 medical students in 2004.

CanSinoBIO's Convidecia™ Approved as Heterologous Booster in Malaysia and Indonesia

Retrieved on: 
Tuesday, March 22, 2022
SSE, Ministry of Health (Bahrain), CanSino Biologics, Convidecia, Vaccination, National Agency of Drug and Food Control of Indonesia, Group, Clinical trial, Public health, Vaccine, Adenoviridae, Research, Certification, Good manufacturing practice, Ageing, HKEX, Immunology, Omicron, Technology, RNA transfection, COVID-19, Ministry, CRM197, Inhalation, Good, GMP

The MOH Malaysia recommends using Convidecia as a heterologous booster for individuals aged 18 and above who have been administered two doses of inactivated COVID-19 vaccine at least three months prior.

Key Points: 
  • The MOH Malaysia recommends using Convidecia as a heterologous booster for individuals aged 18 and above who have been administered two doses of inactivated COVID-19 vaccine at least three months prior.
  • The BPOM recommends that adults who have received inactivated COVID-19 vaccines opt for either Convidecia or an mRNA vaccine as a booster.
  • In addition to Malaysia and Indonesia, Convidecia has been approved for use as a heterologous booster in China and Argentina in national vaccination programs in February 2022 and November 2021, respectively.
  • Recent studies[1]showed that using Convidecia as a heterologous booster, either through intramuscular injection or inhalation, generated greater neutralizing antibody responses than those induced by the homologous inactivated vaccine booster or heterologous recombinant protein vaccine booster.

FDA Approves SPIKEVAX®, Moderna's mRNA COVID-19 Vaccine

Retrieved on: 
Tuesday, February 1, 2022
MHLW, CEO, Safety, Medication, Ministry, Health care, Cell, RNA transfection, EMA, American Medical Association, Research, AMA, COVID-19, Brand Institute, Partnership, MHRA, WHO, World Health Organization, European Medicines Agency, Approximation error, Health Canada, Immunity, World, Ministry of Health, Labour and Welfare, Severe acute respiratory syndrome coronavirus 2, FDA, Degenerative disease, Ministry of Health (Bahrain), Review, Pharmaceutical industry, Health

"This approval indicates that the vaccine has met the FDA's rigorous standards for safety, effectiveness and manufacturing quality required for approval."

Key Points: 
  • "This approval indicates that the vaccine has met the FDA's rigorous standards for safety, effectiveness and manufacturing quality required for approval."
  • Conceptually distinct from other approved COVID-19 vaccine brand names, SPIKEVAX refers to the "spike" glycoprotein, one of the key characteristics of SARS-CoV-2.
  • The mRNA vaccine, SPIKEVAX, gives instructions for cells to produce copies of the "spike" protein, which subsequently becomes a target for the generation of neutralizing antibodies against it.
  • "SPIKEVAX has many of the name characteristics and attributes we pursue when creating a new pharmaceutical or vaccine brand name."

HMI Group Expands Singapore Presence, Doubles Down on Value-Based Care Offering

Retrieved on: 
Wednesday, December 8, 2021
COVID-19, Affordable housing, Accessibility, ICU, Group, Endoscopy, The Straits Times, MOH, Growth, MRT, UNESCO, Continuing education, Bed, Training, Medisave, GP, Frost & Sullivan, Patient, Urology, CEO, Elective surgery, Partnership, Ambulatory care, Gastroenterology, General surgery, Outline of health sciences, Quality, Medical tourism, CHAS, Cardiology, Ministry of Health (Bahrain), Nuclear medicine, Frost, ENT, Global village, Atmosphere, Patients Beyond Borders, Hospital, Emergency, HMI, World Heritage Site, Farrer Park, Ministry, Radiology, Primary care network, Healthcare, Drug, Health insurance, Medicine, Medical device

The move is part of HMI Group's strategy to boost value-based care offering across the country.

Key Points: 
  • The move is part of HMI Group's strategy to boost value-based care offering across the country.
  • "With the investment in OneCare, we are expanding our Singapore presence and doubling down on our value-based care offering in line with the government's '3 Beyonds' push to keep healthcare in Singapore affordable and accessible," said Ms Chin Wei Jia, Group Chief Executive Officer of HMI Group.
  • Alongside the increased stake in OneCare, HMI Group's Singapore expansion strategy includes opening as well as acquiring more private primary care clinics.
  • The Group also holds a majority stake in OneCare Medical, fast-growing primary care clinic chain with 25 clinics across Singapore.